Searchable Databases

Psychedelics & Pain Database

Autoimmune & Inflammation Database

Psychedelics & Pain Database

Research since the 1930’s into the analgesic effects of psychedelics has shown potential across a wide range of compounds and conditions. Through several proposed mechanisms of actions, from neurological to psychological, psychedelic medicines have been shown to have powerful pain reducing effects across a wide variety of conditions. Data continues to mount in research trials across the globe. Search the database below for pain conditions and keep scrolling for the Autoimmune and Inflammation database.

Have a study to add? Email us at info@psychedelicsandpain.org

Psychedelics, Inflammation, & Autoimmune Database

Year Title Compound Condition Journal Author
2013 Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo. (R)-DOI Inflammation PloS one Nau Jr, F., Yu, B., Martin, D. and Nichols, C.D.
2015 Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Classic psychedelics, DMT, LSD, MDMA Immunomodulation Frontiers in immunology Szabo, A.
2017 Psychedelics as medicines: an emerging new paradigm. Serotonergic psychedelics, Classic psychedelics, 5-HT2A receptor agonists. psilocybin, LSD Clinical Pharmacology & Therapeutics Nichols, D.E., Johnson, M.W. and Nichols, C.D.
2017 Psychedelic drugs in biomedicine. Classic psychedelics, LSD, psilocybin Trends in pharmacological sciences Kyzar, E.J., Nichols, C.D., Gainetdinov, R.R., Nichols, D.E. and Kalueff, A.V.
2018 Psychedelics as anti-inflammatory agents. (R)-DOI, 5-HT2A agonists, Classic psychedelics Inflammation International Review of Psychiatry Flanagan, T.W. and Nichols, C.D.
2018 The effects of hallucinogens on gene expression. Serotonergic psychedelics, Classic psychedelics, 5-HT2A receptor agonists. psilocybin, LSD Gene expression Behavioral Neurobiology of Psychedelic Drugs Martin, D.A. and Nichols, C.D.
2019 Effects of psychedelics on inflammation and immunity. LSD, psilocybin, MDMA, ayahuasca, classic psychedelics, cannabidiol, DMT Inflammation, Immunity Advances in psychedelic medicine: state-of-the-art therapeutic applications Szabo, A.
2019 5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model. (R)-DOI Airway inflammation, Asthma Life Sciences Flanagan, T.W., Sebastian, M.N., Battaglia, D.M., Foster, T.P., Cormier, S.A. and Nichols, C.D.
2019 Activation of 5-HT2 receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice. (R)-DOI Inflammation, vascular, cholesterol Scientific Reports Flanagan, T.W., Sebastian, M.N., Battaglia, D.M., Foster, T.P., Maillet, E.L. and Nichols, C.D.
2019 Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Microdose, Microdosing, Classic psychedelics Journal of Psychopharmacology Kuypers, K.P., Ng, L., Erritzoe, D., Knudsen, G.M., Nichols, C.D., Nichols, D.E., Pani, L., Soula, A. and Nutt, D.
2020 Structure–activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore. 2C-H ACS Pharmacology & Translational Science Flanagan, T.W., Billac, G.B., Landry, A.N., Sebastian, M.N., Cormier, S.A. and Nichols, C.D.
2020 5‐HT2 Receptor Activation Differentially Modulates Linker Histone Kinetics and Histone Deacetylase Activity. (R)-DOI, psilocin Linker Histone Kinetics, Histone Deacetylase Activity The FASEB Journal Flanagan, T.W., Billac, G.B. and Nichols, C.D.
2020 Psychedelics as a novel approach to treating autoimmune conditions. Classic psychedelics Immunology Letters Thompson, C. and Szabo, A.
2021 The DMT and psilocin treatment changes CD11b+ activated microglia immunological phenotype. DMT, psilocin BioRXiv Kozłowska, U., Klimczak, A., Wiatr, K. and Figiel, M.
2021 Associations between lifetime classic psychedelic use and cardiometabolic diseases. Classic psychedelics Cardiometabolic Disease Scientific Reports Simonsson, O., Osika, W., Carhart-Harris, R. and Hendricks, P.S.
2021 Pharmahuasca Reduces ROS Production and inflammatory Gene Expression in the Brain in a Model of PTSD: Exploration by RNA Sequencing. Pharmahuasca Gene expression ACS Chemical Neuroscience Kelley, D.P., Venable, K., Billac, G., Destouni, A., Ebenezer, P., Stadler, K., Nichols, C., Barker, S. and Francis, J.
2022 Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers. Psilocybin Immune status, stress response medRxiv Mason, N.L., Szabo, A., Kuypers, K.P., Mallaroni, P.A., de la Torre, R., Reckweg, J.T., Tse, D.H., Hutten, N.R., Feilding, A. and Ramaekers, J.G.
2022 From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. Classic psychedelics, psychedelics Neurodegenerative disorders Journal of Neurochemistry Kozlowska, U., Nichols, C., Wiatr, K. and Figiel, M.
2022 Differential Regulation of Inflammatory Responses Following 5‐HT2 Receptor Activation in Pulmonary Tissues. (R)-DOI Inflammation The FASEB Journal, 36. Flanagan, T.W., Billac, G. and Nichols, C.D.
2022 Psychedelics as potent anti-inflammatory therapeutics. Classic psychedelics, psychedelics Inflammation Neuropharmacology Nichols, C.D.
2022 Psychedelics and anti-inflammatory activity in animal models. (R)-DOI, psilocybin Inflammation In Disruptive Psychopharmacology Flanagan, T.W. and Nichols, C.D.
2023 Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders. Psilocybin Neuropharmacology Wulff, A.B., Nichols, C.D. and Thompson, S.M.
2023 Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation. Psilocybin Comprehensive Psychoneuroendocrinology Burmester, D.R., Madsen, M.K., Szabo, A., Aripaka, S.S., Stenbæk, D.S., Frokjaer, V.G., Elfving, B., Mikkelsen, J.D., Knudsen, G.M. and Fisher, P.M.
Year Title Compound Condition Journal Author